Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 20 de 24
Filter
1.
Open Forum Infectious Diseases ; 9(Supplement 2):S158-S159, 2022.
Article in English | EMBASE | ID: covidwho-2189551

ABSTRACT

Background. Little is known about how social media platforms can be used to increase COVID-19 vaccine intent. We aimed to investigate the effect of social mediabased interventions on vaccine hesitancy in Japan. Methods. We conducted a three-arm randomized controlled trial between 5 November 2021 and 9 January 2022. Japanese aged 20 or above who had not received any COVID-19 vaccine and did not intend to be vaccinated were randomly assigned to one of the following three groups: (i) a control group (with no intervention), (ii) a group with a free chatbot in a popular messenger app called 'LINE,' which provided general information on COVID-19 vaccines and (iii) a group with free webinars where healthcare professionals interactively provided participants with the information on COVID-19 vaccines. The vaccine intention (VI) and three pre-defined Vaccine Confidence Index (VCI), including the importance, safety, and effectiveness of COVID-19 vaccines, were compared. Results. 1,158 persons were included, and the baseline characteristics and demographics were balanced across three groups (Table 1). Among 386 persons assigned to the chatbot group, 231 (59.8%) accessed the chatbot and answered the post-survey. The post-survey revealed no significant difference in VI or VCI between the chatbot group and the control group (Table 2).Among 386 persons assigned to the webinar group, 207 (53.6%) attended webinars and answered the post-survey. The post-survey revealed no difference in VI between the webinar group and the control group. However, the VCI for the importance and the effectiveness significantly increased in the webinar group. There was no difference in VCI for the safety. VCI for the importance and the effectiveness in the control group decreased without any intervention during the study period. Vaccine intention and confidence after interventions Conclusion. While this study demonstrated that neither the chatbot nor the webinar changed VI, VCI for the importance and the effectiveness significantly increased with the webinar intervention. Interactive webinars with live Q and A provided by professionals may have a role in increasing COVID-19 vaccine confidence. Given the degree of vaccine hesitancy worsened over time in the control group, timely intervention is required.

2.
JACC Asia ; 2(7):897-907, 2022.
Article in English | MEDLINE | ID: covidwho-2179892

ABSTRACT

Background: Data on prophylactic anticoagulation are important in understanding the current issues, unmet needs, and optimal management of Japanese COVID-19 patients.

3.
World J Gastroenterol ; 28(48):6791-810, 2022.
Article in English | PubMed Central | ID: covidwho-2201058

ABSTRACT

Various vaccines against severe acute respiratory syndrome coronavirus 2 have been developed in response to the coronavirus disease 2019 (COVID-19) global pandemic, several of which are highly effective in preventing COVID-19 in the general population. Patients with chronic liver diseases (CLDs), particularly those with liver cirrhosis, are considered to be at a high risk for severe COVID-19 and death. Given the increased rates of disease severity and mortality in patients with liver disease, there is an urgent need to understand the efficacy of vaccination in this population. However, the data regarding efficacy and safety of COVID-19 vaccination in patients with CLDs is limited. Indeed, several organ-specific or systemic immune-mediated side effects following COVID-19 vaccination, including liver injury similar to autoimmune hepatitis, have been recently reported. Although the number of cases of vaccine-related liver injury is increasing, its frequency, clinical course, and mechanism remain unclear. Here, we review the current findings on COVID-19 vaccination and liver disease, focusing on: (1) The impact of COVID-19 in patients with CLD;(2) The efficacy, safety, and risk-benefit profiles of COVID-19 vaccines in patients with CLD;and (3) Liver injury following COVID-19 vaccination.

4.
Clinical & Experimental Medicine ; 05:05, 2022.
Article in English | MEDLINE | ID: covidwho-2148801

ABSTRACT

It is unclear whether molnupiravir has a beneficial effect on vaccinated patients infected with the Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We here evaluated the efficacy of molnupiravir in patients with mild-to-moderate coronavirus disease 2019 (COVID-19) during the Omicron variant surge in Fukushima Prefecture, Japan. We enrolled patients with mild-to-moderate COVID-19 who were admitted to hospitals between January and April, 2022. Clinical deterioration after admission was compared between molnupiravir users (n = 230) and non-users (n = 690) after 1:3 propensity score matching. Additionally, we performed forward stepwise multivariate logistic regression analysis to evaluate the association between clinical deterioration after admission and molnupiravir treatment in the 1:3 propensity score-matched subjects. The characteristics of participants in both groups were balanced as indicated by covariates with a standardized mean difference of < 0.1. Regarding comorbidities, there was no imbalance between the two groups, except for the presence of hypertension, dyslipidemia, diabetes mellitus, and cardiac disease. The clinical deterioration rate was significantly lower in the molnupiravir users compared to the non-users (3.90% vs 8.40%;P = 0.034). Multivariate logistic regression analysis demonstrated that receiving molnupiravir was a factor for preventing deterioration (odds ratio 0.448;95% confidence interval 0.206-0.973;P = 0.042), independent of other covariates. This real-world study demonstrates that molnupiravir contributes to the prevention of deterioration in COVID-19 patients after hospitalization during the Omicron variant phase.

5.
Phlebology ; 37(2 Supplement):136-137, 2022.
Article in English | EMBASE | ID: covidwho-2138592

ABSTRACT

Background: Data on thrombosis and current real-world management strategies for anticoagulation therapy are important for an optimal management of patients with coronavirus disease 2019 (COVID-19) Methods: The CLOT-COVID Study (thrombosis and antiCoaguLatiOn Therapy in patients with COVID-19 in Japan Study) was a retrospective, multicenter cohort study enrolling consecutive hospitalized patients with COVID-19 among 16 centers in Japan from April 2021 to September 2021. Also subanalysis is performed for D-dimer at the admission and influence of sex with adjustment confounders with multivariable logistic regression model. Result(s): Among 2894 patients with COVID-19, 1245 (43%) received pharmacological thromboprophylaxis. The proportion of pharmacological thromboprophylaxis increased according to the severity of the COVID-19 in9.8% with mild COVID-19, 61% with moderate COVID-19, and 97% with severe COVID-19. During the hospitalization, 38 patients (1.3%)and 126 (4.4%) underwent ultrasound examinations for the lower extremities and contrastenhanced computed tomography examinations, respectively, and 55 (1.9%) developed thrombosis, mostly venous thromboembolism(71%). The incidence of thrombosis increased according to the severity of the COVID-19 in 0.2% with mild COVID-19, 1.4%withmoderate COVID-19, and 9.5%with severe COVID-19. Major bleeding occurred in 57 patients (2.0%) and 158 (5.5%) died, and 81% of them were due to respiratory failure from COVID-19 pneumonia. The higher D-dimer levels in the 3rd tertile (>=1.1 mug/mL) in 2,771 patients who had D-dimer levels measured at admission. were independently associated with a higher risk of VTE during hospitalization (adjusted odds ratio 4.83 [95% confidence interval 1.93-12.11;P<0.001];reference=1st tertile).Men had more severe status of the COVID-19 at admission compared with women (Mild: 57% versus 66%, Moderate: 34% versus 29%, and Severe: 9.1% versus 5.7%, P < 0.001). During the hospitalization, men more often developed thrombosis than women (2.5% [95%CI, 1.9-3.3%] versus 0.8% [95%CI, 0.4- 1.6%], P = 0.001). Men had numerically higher incidences of thrombosis than women in all subgroups of the worst severity of COVID-19during the hospitalization (Mild: 0.3% versus 0.0%, Moderate: 1.6% versus 1.0%, and Severe: 11.1% versus 4.3%) Conclusion(s): In the large-scale observational study, pharmacological thromboprophylaxis for hospitalized patients was common especially in patients with severe COVID-19. The overall incidence of thrombosis was substantially low with an increased incidence according to the severity of the COVID-19 in Japan. In contrast to previous studies outside Japan, the risk of thrombosis in Japanese patients with COVID-19 may be relatively low, and racial differences may have to be considered. In subanalysis higher D-dimer levels at admission were associated with a higher risk of VTE events during hospitalization. Men had more severe status of the COVID-19 than women, and the risk of development of thrombosis was higher in men compared with women.

6.
16th IEEE International Conference on Service-Oriented System Engineering, SOSE 2022 ; : 147-153, 2022.
Article in English | Scopus | ID: covidwho-2136482

ABSTRACT

Due to the spread of COVID-19, people are starting to be more aware and careful when touching any devices in public. To reduce physical contact with public devices, we have developed a method that enables users to interact with many kinds of public devices using the browser on their smartphones. This method is called Chameleon because it resembles the ability of the animal chameleon to change its color according to its surrounding environment. We have developed the prototype system to confirm the mechanism of Chameleon. Then, we have applied the Chameleon method to two practical systems in the campus of Nagasaki University that is expected to be used by multiple users. These two systems are a Certificate Issuance System for students and a Digital Signage System, that provides directions to campus visitors. Through these experiences, we confirmed the availability of the Chameleon method as the new type of the browser included not only Web server browsing functions but also public device operation functions. © 2022 IEEE.

7.
American Journal of Respiratory and Critical Care Medicine ; 206(9):1182-1183, 2022.
Article in English | Web of Science | ID: covidwho-2126283
8.
Mathematical Biosciences and Engineering ; 19(12):13137-13151, 2022.
Article in English | Scopus | ID: covidwho-2055536

ABSTRACT

The basic reproduction number, R0, plays a central role in measuring the transmissibility of an infectious disease, and it thus acts as the fundamental index for planning control strategies. In the present study, we apply a branching process model to meticulously observed contact tracing data from Wakayama Prefecture, Japan, obtained in early 2020 and mid-2021. This allows us to efficiently estimate R0 and the dispersion parameter k of the wild-type COVID-19, as well as the relative transmissibility of the Delta variant and relative transmissibility among fully vaccinated individuals, from a very limited data. R0 for the wild type of COVID-19 is estimated to be 3.78 (95% confidence interval [CI]: 3.72–3.83), with k = 0.236 (95% CI: 0.233–0.240). For the Delta variant, the relative transmissibility to the wild type is estimated to be 1.42 (95% CI: 0.94–1.90), which gives R0 = 5.37 (95% CI: 3.55–7.21). Vaccine effectiveness, determined by the reduction in the number of secondary transmissions among fully vaccinated individuals, is estimated to be 91% (95% CI: 85%–97%). The present study highlights that basic reproduction numbers can be accurately estimated from the distribution of minor outbreak data, and these data can provide further insightful epidemiological estimates including the dispersion parameter and vaccine effectiveness regarding the prevention of transmission. © 2022 the Author(s), licensee AIMS Press.

9.
Frontiers in Immunology ; 13, 2022.
Article in English | EMBASE | ID: covidwho-2005865

ABSTRACT

Sparked by the development of genome sequencing technology, the quantity and quality of data handled in immunological research have been changing dramatically. Various data and database platforms are now driving the rapid progress of machine learning for immunological data analysis. Of various topics in immunology, T cell receptor repertoire analysis is one of the most important targets of machine learning for assessing the state and abnormalities of immune systems. In this paper, we review recent repertoire analysis methods based on machine learning and deep learning and discuss their prospects.

10.
Journal of Crohn's & colitis ; 16(Suppl 1):i074-i077, 2022.
Article in English | EuropePMC | ID: covidwho-1999610

ABSTRACT

Background Immune responses to the SARS-CoV-2 vaccination may be influenced by immunomodulatory drugs (IMDs). We investigated the immune responses and safety in fully vaccinated Japanese patients with IBD. Methods IBD patients and control subjects at 39 institutes were invited to participate in the study from March to October 2021. Blood sample collections to measure anti-SARS-CoV-2 spike IgG antibody titers were planned pre-1st vaccination, pre-2nd vaccination, and at 4 weeks, 3 months and 6 months post-2nd vaccination. Immune responses were compared between groups, considering baseline characteristics and IMD treatments. (UMIN000043545) The interim analyses presented here include mainly data from the 4-weeks post-2nd vaccination time-point. Results In total, 679 IBD patients and 203 controls were enrolled (Table 1). The IBD group received the BNT162b2 vaccine (86.2%) and the mRNA-1273 vaccine (12.5%), and the control group received the BNT162b2 vaccine (86.9%) and the mRNA-1273 vaccine (12.1%). Only 4 cases (0.7%) in the IBD group and 2 (1.0%) in the control group were infected with COVID-19. Adverse events of 2nd vaccination occurred in 48.4% of the IBD group and 35.1% of the control group. Comparison between administrated and non-administrated IBD patients for each IMD revealed an attenuated genomic mean titer (GMT [U/mL]) in those taking systemic steroids (18.85 vs 31.24), anti-TNF monotherapy (28.31 vs 42.99), anti-TNF therapy+ immunomodulator (IM) (12.86 vs 35.26), vedolizumab+IM (19.49 vs 30.39), ustekinumab+IM (20.44 vs 30.79), and tofacitinib (9.54 vs 32.08), but not in those taking oral 5-ASA (29.50 vs 32.40), or vedolizumab (41.85 vs 40.20) and ustekinumab (55.56 vs 39.26) monotherapies. Estimated least square means of the GMT by a multiple linear regression model are shown in Table 2. GMTs were significantly influenced by increasing age and allergy (51.2, 95%CI 42.1–62.3;p=0.0293), and tended to be influenced by COVID-19 infection (139.1, 41.0–472.2;p=0.0572). Sex, smoking, drinking, IBD, and adverse events of 2nd vaccination did not affect the GMT. The GMT was significantly higher for mRNA-1273 (90.3 [60.8–134.1]) than for BNT162b2 (39.6 [35.2–44.6], p= 0.0001). Systemic steroids (22.9 [13.9–37.7], p=0.0119), IM (24.2 [18.7–31.4], p<0.0001), anti-TNF agents (20.8 [15.3–28.3], p<0.0001), vedolizumab (25.2 [15.0–42.2], p=0.0409), ustekinumab (28.9 [18.5–45.0], p=0.0754), and tofacitinib (5.5 [2.8–10.9], p<0.0001), but not oral 5-ASA (39.1 [31.9–47.9], p=0.3225), attenuated GMTs at 4 weeks post-2nd vaccination (Table 2). Conclusion Aging and most IMD options attenuated immunogenicity in fully vaccinated IBD patients. Prioritization of a booster vaccination should be considered for IBD patients treated with IMDs.

11.
J Atheroscler Thromb ; : 63702-63702, 2022.
Article in English | J-STAGE | ID: covidwho-1969707

ABSTRACT

AIM: There is scarce data on the impact of age on clinical outcomes in patients with coronavirus disease 2019 (COVID-19). METHOD: The CLOT-COVID Study was a retrospective, multicenter cohort study enrolling 2894 consecutive hospitalized patients with COVID-19 among 16 centers in Japan from April 2021 to September 2021. We divided the entire cohort into five groups according to age strata;-19, 20-39, 40-59, 60-79, and 80- years. RESULTS: Most patients under 19 had mild COVID-19 on admission (99%), while older patients had more severe COVID-19. The incidence rates of clinical outcomes during hospitalization in patients aged </= 19, 20-39, 40-59, 60-79, and 80 >/= years were 0.0%, 0.5%, 2.2%, 2.7%, and 1.5% for thrombosis;0.0%, 1.2%, 1.5%, 3.4%, and 2.0% for major bleeding;and 0.0%, 0.4%, 2.0%, 12.1%, and 16.8% for all-cause death, respectively. In the stratified analysis according to COVID-19 severity on admission, the incidences of thrombosis were generally higher among patients with more severe status, although those were not significantly different among age strata in all sub-types of COVID-19 severity. However, the incidences of all-cause death were significantly higher with increasing age in all sub-types of COVID-19 severity. CONCLUSIONS: In the current large observational study of patients with COVID-19, the risk of mortality became markedly higher with increased age. However, the risks of thrombosis and major bleeding did not necessarily increase as age increases, which seemed to be consistent irrespective of COVID-19 severity on admission.

12.
Gastroenterology ; 162(7):S-1005, 2022.
Article in English | EMBASE | ID: covidwho-1967390

ABSTRACT

Background: Immune responses to the SARS-CoV-2 vaccination may be influenced by immunomodulatory drugs (IMDs). We investigated the immune responses and safety in fully vaccinated Japanese patients with IBD. Subjects and Methods: IBD patients and control subjects at 39 institutes were invited to participate in the study from March to October 2021. Blood sample collections to measure anti-SARS-CoV-2 spike IgG antibody titers were planned pre-1st vaccination, pre-2nd vaccination, and at 4 weeks, 3 months and 6 months post-2nd vaccination. Immune responses were compared between groups, considering baseline characteristics and IMD treatments. (UMIN000043545) The interim analyses presented here include mainly data from the 4-weeks post-2nd vaccination time-point. Results: In total, 679 IBD patients and 203 controls were enrolled (Table 1). The IBD group received the BNT162b2 vaccine (86.2%) and the mRNA-1273 vaccine (12.5%), and the control group received the BNT162b2 vaccine (86.9%) and the mRNA-1273 vaccine (12.1%). Only 4 cases (0.7%) in the IBD group and 2 (1.0%) in the control group were infected with COVID-19. Adverse events of 2nd vaccination occurred in 48.4% of the IBD group and 35.1% of the control group. Comparison between administrated and non-administrated IBD patients for each IMD revealed an attenuated genomic mean titer (GMT [U/mL]) in those taking systemic steroids (18.85 vs 31.24), anti-TNF monotherapy (28.31 vs 42.99), anti- TNF therapy+ immunomodulator (IM) (12.86 vs 35.26), vedolizumab+IM (19.49 vs 30.39), ustekinumab+IM (20.44 vs 30.79), and tofacitinib (9.54 vs 32.08), but not in those taking oral 5-ASA (29.50 vs 32.40), or vedolizumab (41.85 vs 40.20) and ustekinumab (55.56 vs 39.26) monotherapies. Estimated least square means of the GMT by a multiple linear regression model are shown in Table 2. GMTs were significantly influenced by increasing age and allergy (51.2, 95%CI 42.1-62.3;p=0.0293), and tended to be influenced by COVID- 19 infection (139.1, 41.0-472.2;p=0.0572). Sex, smoking, drinking, IBD, and adverse events of 2nd vaccination did not affect the GMT. The GMT was significantly higher for mRNA- 1273 (90.3 [60.8-134.1]) than for BNT162b2 (39.6 [35.2-44.6], p= 0.0001). Systemic steroids (22.9 [13.9-37.7], p=0.0119), IM (24.2 [18.7-31.4], p<0.0001), anti-TNF agents (20.8 [15.3-28.3], p<0.0001), vedolizumab (25.2 [15.0-42.2], p=0.0409), ustekinumab (28.9 [18.5-45.0], p=0.0754), and tofacitinib (5.5 [2.8-10.9], p<0.0001), but not oral 5- ASA (39.1 [31.9-47.9], p=0.3225), attenuated GMTs at 4 weeks post-2nd vaccination (Table 2). Conclusion: Aging and most IMD options attenuated immunogenicity in fully vaccinated IBD patients. Prioritization of a booster vaccination should be considered for IBD patients treated with IMDs. (Table Presented) (Table Presented)

14.
Acta Medica Nagasakiensia ; 65(2):67-71, 2021.
Article in English | EMBASE | ID: covidwho-1856303

ABSTRACT

The relationship between the severity of COVID-19, hyperinflammation, and intravascular coagulopathy is of critical importance. We report on a case of severe COVID-19 pneumonia treated with favipiravir during the earliest phase of the pandemic. The present case showed improvement in SARS-CoV-2 viral load and the presence of SARS-CoV-2 IgG with decreased radiological evidence of pulmonary infiltration. Moreover, the levels of serum IL-6 and TNF-α did not increase markedly. However, the hypoxia failed to recover, leading to the patient’s death due to possible pulmonary thrombosis, because D-dimer was markedly elevated, and an electrocardiogram showed typical changes. At present, the fact that some COVID-19 patients with mild to moderate symptoms suddenly die at home has become a major issue in Japan. These findings suggest that additional treatment with anti-coagulants should be considered in some COVID-19 patients at risk of hypercoagulation to prevent sudden death from pulmonary thrombosis.

15.
11th IEEE International Conference on Consumer Electronics, ICCE-Berlin 2021 ; 2021-November, 2021.
Article in English | Scopus | ID: covidwho-1769603

ABSTRACT

Due to the spread of COVID-19, people are starting to be more aware and careful when touching any devices in the public. In this paper, we proposed a method that could help reduce physical contacts with public devices using smartphone. This method is called Chameleon and we have developed the Chameleon so that it functions as an application that can control any kinds of public devices with minimal modifications.To confirm the effectiveness of the Chameleon, we have applied the method to two different systems in the campus of Nagasaki University that is expected to be used by multiple users. The two systems are a Digital Signage System, a system that provides directions to campus visitors, and a PIN type Smart Lock, a system that acts as a door lock. © 2021 IEEE.

16.
Open Forum Infectious Diseases ; 8(SUPPL 1):S321-S322, 2021.
Article in English | EMBASE | ID: covidwho-1746557

ABSTRACT

Background. Japan has one of the highest vaccine hesitancy rates in the world. According to a previous study, less than 30% of people strongly agreed that vaccines were safe, important, or effective. We created a COVID-19 vaccine information chatbot in a popular messenger app in Japan to answer COVID-19 vaccine frequently asked questions (FAQs) via text messages. We assessed the impact of chatbot text messages on COVID-19 vaccine hesitancy by conducting a cross-sectional survey among chatbot users. Methods. LINE is the most popular messenger app in Japan;about 86 million people in Japan (roughly two-thirds of the population) use this messenger app. Corowa-kun, a free chatbot, was created in LINE on February 6, 2021. Corowa-kun provides instant, automated answers to frequently asked COVID-19 vaccine questions. A cross-sectional survey assessing COVID-19 vaccine hesitancy was conducted via Corowa-kun during April 5 to 12, 2021. We included persons ages 16 years old and older who had not received a COVID-19 vaccine. The survey was written in Japanese and consisted of 21 questions. Corowa-kun is the mascot of an online chatbot. This chatbot in LINE is used to answer COVID-19 vaccine frequently asked questions (FAQs) via text messages. As of May 10th, 70 FAQs are available. Results. A total of 59,676 persons used Corowa-kun during February to April 2021. The most commonly accessed message categories were: "I have (select comorbidity), can I get a COVID-19 vaccine?" (23%);followed by questions on adverse reactions (22%) and how the vaccine works (20%). 10,192 users (17%) participated in the survey. Median age was 55 years (range 16 to 97), and most were female (74%). Intention to receive a COVID-19 vaccine increased from 59% to 80% after using Corowa-kun (p < 0.01). Overall, 20% remained hesitant: 16% (1,675) were unsure, and 4% (364) did not intend to be vaccinated. Factors associated with vaccine hesitancy were: age 16 to 34 (odds ratio [OR] = 3.7, 95% confidential interval [CI]: 3.0-4.6, compared to age ≥65), female sex (OR = 2.4, Cl: 2.1-2.8), and history of another vaccine side-effect (OR = 2.5, Cl: 2.2-2.9). Being a physician (OR = 0.2, Cl: 0.1-0.4) and having received a flu vaccine the prior season (OR = 0.4, Cl: 0.3-0.4) were protective. COVID-19 vaccine acceptance increased and hesitancy decreased after using Corowa-kun, Japan, 2021 (n=10,192) ∗There was a statistically significant difference in responses between before and after using Corowa-kun (p < 0.01, Chi-square test). Univariable logistic regression models of factors associated with COVID-19 vaccine hesitancy, Japan, 2021 (n=10,192) Ref: reference NA: Logistic regression was not performed due to too small number (n≤3) Conclusion. Corowa-kun reduced vaccine hesitancy by providing COVID-19 vaccine information in a messenger app. Mobile messenger apps could be leveraged to increase COVID-19 vaccine acceptance.

17.
Journal of Crohn's and Colitis ; 16:i076, 2022.
Article in English | EMBASE | ID: covidwho-1722302

ABSTRACT

Background: Immune responses to the SARS-CoV-2 vaccination may be influenced by immunomodulatory drugs (IMDs). We investigated the immune responses and safety in fully vaccinated Japanese patients with IBD. Methods: IBD patients and control subjects at 39 institutes were invited to participate in the study from March to October 2021. Blood sample collections to measure anti-SARS-CoV-2 spike IgG antibody titers were planned pre-1st vaccination, pre-2nd vaccination, and at 4 weeks, 3 months and 6 months post-2nd vaccination. Immune responses were compared between groups, considering baseline characteristics and IMD treatments. (UMIN000043545) The interim analyses presented here include mainly data from the 4-weeks post-2nd vaccination time-point. Results: In total, 679 IBD patients and 203 controls were enrolled (Table 1). The IBD group received the BNT162b2 vaccine (86.2%) and the mRNA-1273 vaccine (12.5%), and the control group received the BNT162b2 vaccine (86.9%) and the mRNA-1273 vaccine (12.1%). Only 4 cases (0.7%) in the IBD group and 2 (1.0%) in the control group were infected with COVID-19. Adverse events of 2nd vaccination occurred in 48.4% of the IBD group and 35.1% of the control group. Comparison between administrated and nonadministrated IBD patients for each IMD revealed an attenuated genomic mean titer (GMT [U/mL]) in those taking systemic steroids (18.85 vs 31.24), anti-TNF monotherapy (28.31 vs 42.99), anti-TNF therapy+ immunomodulator (IM) (12.86 vs 35.26), vedolizumab+IM (19.49 vs 30.39), ustekinumab+IM (20.44 vs 30.79), and tofacitinib (9.54 vs 32.08), but not in those taking oral 5-ASA (29.50 vs 32.40), or vedolizumab (41.85 vs 40.20) and ustekinumab (55.56 vs 39.26) monotherapies. Estimated least square means of the GMT by a multiple linear regression model are shown in Table 2. GMTs were significantly influenced by increasing age and allergy (51.2, 95%CI 42.1-62.3;p=0.0293), and tended to be influenced by COVID-19 infection (139.1, 41.0-472.2;p=0.0572). Sex, smoking, drinking, IBD, and adverse events of 2nd vaccination did not affect the GMT. The GMT was significantly higher for mRNA-1273 (90.3 [60.8-134.1]) than for BNT162b2 (39.6 [35.2-44.6], p= 0.0001). Systemic steroids (22.9 [13.9-37.7], p=0.0119), IM (24.2 [18.7-31.4], p<0.0001), anti-TNF agents (20.8 [15.3-28.3], p<0.0001), vedolizumab (25.2 [15.0-42.2], p=0.0409), ustekinumab (28.9 [18.5-45.0], p=0.0754), and tofacitinib (5.5 [2.8-10.9], p<0.0001), but not oral 5-ASA (39.1 [31.9-47.9], p=0.3225), attenuated GMTs at 4 weeks post-2nd vaccination (Table 2). Conclusion: Aging and most IMD options attenuated immunogenicity in fully vaccinated IBD patients. Prioritization of a booster vaccination should be considered for IBD patients treated with IMDs.

18.
10th IEEE Global Conference on Consumer Electronics, GCCE 2021 ; : 597-598, 2021.
Article in English | Scopus | ID: covidwho-1672680

ABSTRACT

Due to the spread of new coronavirus infections, it is desirable to allow people to use public devices such as PIN type smart locks or vending machines without touching them directly. Therefore, we developed a method that enables contactless operation of various public devices using personal smartphones while reducing the impact on existing public devices. This method imitates chameleons of the animal. Therefore, we call it chameleon. We developed the chameleon based on Web application and applied it to PIN type smart locks. Then, we confirmed the effectiveness of the chameleon as the method of contactless operation. © 2021 IEEE.

20.
Annals of Oncology ; 32:S320, 2021.
Article in English | EMBASE | ID: covidwho-1338339

ABSTRACT

Background: An emergency framework was set to confront the first wave COVID-19 pandemic at the medical oncology division for breast cancer at the Cancer Institute Hospital of JFCR, Tokyo, in March 2020. Medical therapy was classified into two phases in our guideline. In the initial phase, workload or patients' visit was to be reduced without impairing disease control and survival. In the successive phase under restriction of medical resources, only therapies with higher priority and alternate therapies were to be practiced. Whereas no significant effect on medical practice was observed during first wave pandemic, actual impact was evaluated in this study. Methods: Among patients in our division from April to May 2020, cases of treatment change, postponement of treatment introduction, treatment interruption, long-term prescription, telephone consultation, postponement of visit, reference to other hospital, and COVID-19 diagnosis were retrospectively searched from medical records. Results: There were estimated 984 patients, 389 perioperative and 595 metastatic, of whom 119(12%) were affected by COVID-19. The breakdown is 7 cases of treatment changes, 7 cases of postponements of introduction, 20 cases of interruptions, 12 cases of long-term prescriptions of oral chemotherapy and molecular targeted therapy, 36 cases of prescriptions by telephone consultation, 94 cases of postponements of visit, 3 cases of reference to other hospital, and 4 cases of fever for which COVID-19 infection could not be denied. Conclusion: 12% of patients in the division of medical oncology at the breast center changed their treatment or schedule of visit. Treatment change that could affect breast cancer survival were 2 cases of cancellation of adjuvant chemotherapy. The effect might have been minimized by formulation of a COVID-19 guideline prior to the pandemic.

SELECTION OF CITATIONS
SEARCH DETAIL